Neoplasms, Malignant Clinical Trial
Official title:
Radiofrequency Ablation (RFA) Of Tumors Acquired In Childhood: A Phase II Study
NCT number | NCT00868647 |
Other study ID # | RFAII |
Secondary ID | |
Status | Suspended |
Phase | Phase 2 |
First received | March 23, 2009 |
Last updated | August 28, 2009 |
Start date | June 2007 |
Verified date | August 2009 |
Source | Seattle Children's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This is a single-center, Phase II study including only patients on whom a decision to
conduct radiofrequency ablation (RFA) has already been made. The primary objective of this
study assess if quality of life was improved by RFA as assessed at baseline, 3 and
potentially 6 and 12 months following RFA for the benign lesions.
RFA is an imaging guided percutaneous or intra-operative procedure that uses a probe on the
end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by
heating the probe (using an electrical current alternating at radio frequency) which raises
the temperature of the tumor potentially causing irreversible cell death.
RF ablation is an alternative for local tumor control when other treatments (surgery,
radiotherapy or chemotherapy) are not feasible (less effective or at higher risk). Thermal
ablation at times is the only remaining alternative for patient cure, prolonged survival or
palliation. Cryotherapy, and microwave, laser and focused ultrasound are alternative thermal
ablation techniques used in adults but there has been no experience in children with these
alternative methods.
To be eligible for this study, patients must have acquired lesions at < 21 years of age
(central nervous system lesions are excluded from this study). Study participants will have
the RFA procedure performed at Seattle Children's and will have follow-up evaluations at
various time points post-RFA.
Status | Suspended |
Enrollment | 60 |
Est. completion date | |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Lesion acquired in childhood (at <21 years of age) - Any lesion location except CNS - Any malignant tumor or metastasis - Any benign lesion (e.g. desmoids, venous or lymphatic vascular anomalies, aneurysmal bone cysts, osteoid osteoma, tongue hypertrophy, or painful neuropathy) - Patients with malignant disease have had histologic confirmation of disease at initial diagnosis. - = 90 day life expectancy - Potential benefit of RFA outweighs risk as determined by PI - Other local tumor control measures are not recommended for malignant lesion based on review in multidisciplinary team conference or the patient refuses recommended local tumor control measures - The patient is not expected to become short of breath at rest after RFA (forced vital capacity =33% of normal by pulmonary function tests) if pulmonary RFA is considered Exclusion Criteria: - Patients with uncontrolled infection. - Patients with co-morbidities affecting inclusion criteria above. - Patients who are pregnant and/or breastfeeding. - Patients who had a change in chemotherapy within one month before RFA - Patients who have planned change in chemotherapy and/or radiation therapy (to same site as RFA) interventions within the first three months following RFA. - Patients should not be considered for pulmonary RFA if they have poorly compliant lungs (recently required mechanical ventilation) or require supplemental oxygen. |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Seattle Children's Hospital | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Seattle Children's Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess if quality of life was improved by RFA for the benign lesions | baseline, 3 months and potentially 6 and 12 months following RFA | No | |
Secondary | Assess the response to RF ablative therapy by pain relief from painful benign or malignant lesions. | baseline, 3 months and potentially 6 and 12 months following RFA | No | |
Secondary | Evaluate the rate of short-term ablation of benign lesions produced by RFA | baseline, 3 months and potentially 6 and 12 months following RFA | No | |
Secondary | Assess toxicity related to all RFA procedures using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 | within 3 months (potentially 6-12 months) following RFA | Yes | |
Secondary | Assess the response to RFA by malignant tumor markers (e.g. AFP) | 1, 3, 6, and 12 months following RFA | No | |
Secondary | Assess if quality of life was improved by RFA for patients with malignant lesions | baseline, 3, 6 and 12 months | No | |
Secondary | Evaluate the proportion of malignant lesions that show short-term ablation produced by RFA. | 3 months post Radiofrequency Ablation (RFA), as compared to 1 month post RFA imaging | No | |
Secondary | Determine the rate of durable ablation in malignant lesions that achieve short-term ablation by RFA | 12 months post RFA | No | |
Secondary | Assess the time to malignant tumor progression (as defined by RECIST) of lesions treated with RFA | 1, 3, 6, and 12 months post RFA | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01193595 -
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01001221 -
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
|
Phase 1/Phase 2 | |
Completed |
NCT01095302 -
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT01087021 -
Effect of Cabazitaxel on the QTc Interval in Cancer Patients
|
Phase 1 | |
Completed |
NCT01021150 -
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT01063946 -
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
|
Phase 1 | |
Terminated |
NCT02706197 -
Oxygen Measurements in Subcutaneous Tumors by EPR Oximetry Using OxyChip
|
N/A | |
Terminated |
NCT03321903 -
EPR Tumor Oximetry With CE India Ink
|